Hepatitis C virus inhibitors
US-9227940-B2 · Jan 5, 2016 · US
Hepatitis C virus inhibitors
US9636375B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9636375-B2 |
| Application number | US-201514936419-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 9, 2015 |
| Priority date | May 20, 2002 |
| Publication date | May 2, 2017 |
| Grant date | May 2, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Hepatitis C virus inhibitors are disclosed having the general formula: wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting HCV NS3 protease, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9636375B2 cover?
- Hepatitis C virus inhibitors are disclosed having the general formula: wherein R 1 , R 2 , R 3 , R′, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
- Who is the assignee on this patent?
- Bristol Myers Squibb Co
- What technology area does this patent fall under?
- Primary CPC classification A61K38/06. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).